<DOC>
	<DOC>NCT00092001</DOC>
	<brief_summary>The purpose of this study is to test whether SU011248 has activity and is safe in patients with metastatic non-small cell lung cancer (NSCLC) who have failed a platinum-containing regimen and docetaxel.</brief_summary>
	<brief_title>Study Of SU011248 In Patients With Metastatic Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Histologically confirmed advanced or metastatic NonSmall Cell Lung Cancer that cannot be cured with surgery, radiation, or combination thereof No more than 2 prior chemotherapy treatments including treatment with a platinum containing therapy Evidence of measurable disease by radiographic technique Male or Female, 18 years or older ECOG performance status of 0 or 1 Resolution of all acute toxicities of prior therapies Adequate organ function Major surgery or radiation therapy within 4 weeks Severe hemorrhage within 4 weeks Previous treatment with antiangiogenesis agents Diagnosis of second malignancy within last five 5 years History of or known brain metastases, spinal cord compression, or carcinomatous meningitis Known HIV Serious acute or chronic illness Current treatment on another clinical trial Pregnant or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Non-small cell lung cancer, carcinoma, sunitinib, Phase 2</keyword>
</DOC>